Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 327Gynecologic 15Thoracic 10Gastrointestinal 9Genitourinary 8Head & Neck 4Sarcoma 3Endocrine 3CNS 2Other solid neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 2Brain Neoplasms 2

Interventions

Trastuzumab 20Radiosurgery 15Magnetic Resonance Spectroscopy 15Capecitabine 14Lapatinib 12Radiotherapy 11Specimen Handling 10Cyclophosphamide 9trastuzumab deruxtecan 8Temozolomide 8Docetaxel 8Paclitaxel 7Gemcitabine 6Cisplatin 6sacituzumab govitecan 5Vinorelbine 5Therapeutics 5Spinal Puncture 5Flow Cytometry 5tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Methotrexate 4Irinotecan 4Fluorodeoxyglucose F18 4Dexamethasone 4Bevacizumab 4temsirolimus 3pyrotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Fulvestrant × CNS × Clear all
NCT03803761 2023-09-25

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Sun Yat-sen University

Phase 2 Unknown
34 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡